SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
bcp12177-sup-0001-si.doc25K

Appendix S1

Quantification of bosentan and its major metabolites in plasma

bcp12177-sup-0002-si.docx15K

Table S1

Point estimates (95% CI) of bosentan compared to steady-state values in healthy participants with differing CYP2C9 and OATP1B1 polymorphisms before and during clarithromycin

bcp12177-sup-0003-si.docx15K

Table S2

Point estimates (95% CI) of bosentan metabolites compared to steady-state values in healthy participants with differing CYP2C9 and OATP1B1 polymorphisms before and during clarithromycin

bcp12177-sup-0004-si.docx18K

Table S3

Geometric means (95% CI) of bosentan and its metabolites in healthy participants with differing CYP2C9 and OATP1B1 polymorphisms after single dose, at steady-state and during clarithromycin

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.